{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:06:36Z","timestamp":1793066796593,"version":"4.5.0"},"reference-count":73,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Enzyme Inhibition and Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/14756366.2026.2700842","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T11:13:56Z","timestamp":1786446836000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Structure-based screening and identification of a novel Aurora-A-targeting peptide with antiproliferative activity against prostate cancer cells"],"prefix":"10.1080","volume":"41","author":[{"given":"Bei-Bei","family":"Huang","sequence":"first","affiliation":[{"name":"Drug Clinical Trial Facility Office, The Affiliated Hospital of Xuzhou Medical University","place":["Xuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijing","family":"Jiang","sequence":"additional","affiliation":[{"name":"Drug Clinical Trial Facility Office, The Affiliated Hospital of Xuzhou Medical University","place":["Xuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaozhi","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis, China Pharmaceutical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Jia","family":"Ge","sequence":"additional","affiliation":[{"name":"Drug Clinical Trial Facility Office, The Affiliated Hospital of Xuzhou Medical University","place":["Xuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis, China Pharmaceutical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"issue":"6","key":"e_1_3_3_2_1","first-page":"485","article-title":"Prostate cancer statistics, 2025","volume":"75","author":"Kratzer TB","year":"2025","unstructured":"Kratzer TB, Mazzitelli N, Star J, Dahut WL, Jemal A, Siegel RL. Prostate cancer statistics, 2025. CA Cancer J Clin. 2025;75(6):485\u2013497.","journal-title":"CA Cancer J Clin"},{"issue":"13","key":"e_1_3_3_3_1","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.3390\/cancers17132137","article-title":"Advances and challenges in prostate cancer diagnosis: a comprehensive review","volume":"17","author":"Kania E","year":"2025","unstructured":"Kania E, Janica M, Nesterowicz M, Modzelewski W, Cybulski M, Janica J. Advances and challenges in prostate cancer diagnosis: a comprehensive review. Cancers (Basel). 2025;17(13):2137.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"e_1_3_3_4_1","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.coph.2008.07.005","article-title":"Targeting the androgen receptor pathway in prostate cancer","volume":"8","author":"Chen Y","year":"2008","unstructured":"Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol. 2008;8(4):440\u2013448.","journal-title":"Curr Opin Pharmacol"},{"issue":"9","key":"e_1_3_3_5_1","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2009.24.6819","article-title":"Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate","volume":"28","author":"Reid AHM","year":"2010","unstructured":"Reid AHM, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol. 2010;28(9):1489\u20131495.","journal-title":"J Clin Oncol"},{"issue":"21","key":"e_1_3_3_6_1","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono JS","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995\u20132005.","journal-title":"N Engl J Med"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.07.028"},{"issue":"11","key":"e_1_3_3_8_1","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis ES","year":"2014","unstructured":"Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371(11):1028\u20131038.","journal-title":"N Engl J Med"},{"issue":"1","key":"e_1_3_3_9_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13008-018-0040-6","article-title":"The functional diversity of Aurora kinases: a comprehensive review","volume":"13","author":"Willems E","year":"2018","unstructured":"Willems E, Dedobbeleer M, Digregorio M, Lombard A, Lumapat PN, Rogister B. The functional diversity of Aurora kinases: a comprehensive review. Cell Div. 2018;13(1):7.","journal-title":"Cell Div"},{"key":"e_1_3_3_10_1","first-page":"118","article-title":"Aurora kinases: new molecular targets for the therapy of aggressive thyroid cancers","volume":"96","author":"Baldini E","year":"2016","unstructured":"Baldini E, et al. Aurora kinases: new molecular targets for the therapy of aggressive thyroid cancers. Anti-Cancer Drugs Nat Synth Cell. 2016;96:118.","journal-title":"Anti-Cancer Drugs Nat Synth Cell"},{"issue":"5","key":"e_1_3_3_11_1","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.bbamcr.2014.01.019","article-title":"Aurora-A controls cancer cell radio-and chemoresistance via ATM\/Chk2-mediated DNA repair networks","volume":"1843","author":"Sun H","year":"2014","unstructured":"Sun H, Wang Y, Wang Z, Meng J, Qi Z, Yang G. Aurora-A controls cancer cell radio-and chemoresistance via ATM\/Chk2-mediated DNA repair networks. Biochim Biophys Acta. 2014;1843(5):934\u2013944.","journal-title":"Biochim Biophys Acta"},{"issue":"13","key":"e_1_3_3_12_1","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1158\/0008-5472.CAN-18-3397","article-title":"Aurora A inhibition eliminates myeloid cell-mediated immunosuppression and enhances the efficacy of anti\u2013PD-L1 therapy in breast cancer","volume":"79","author":"Yin T","year":"2019","unstructured":"Yin T, Zhao Z-B, Guo J, Wang T, Yang J-B, Wang C, Long J, Ma S, Huang Q, Zhang K, et al. Aurora A inhibition eliminates myeloid cell-mediated immunosuppression and enhances the efficacy of anti\u2013PD-L1 therapy in breast cancer. Cancer Res. 2019;79(13):3431\u20133444.","journal-title":"Cancer Res"},{"issue":"1","key":"e_1_3_3_13_1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1535-6108(02)00235-0","article-title":"AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol","volume":"3","author":"Anand S","year":"2003","unstructured":"Anand S, Penrhyn-Lowe S, Venkitaraman AR. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell. 2003;3(1):51\u201362.","journal-title":"Cancer Cell"},{"issue":"4","key":"e_1_3_3_14_1","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1023\/A:1023789416385","article-title":"The Aurora kinases: role in cell transformation and tumorigenesis","volume":"22","author":"Katayama H","year":"2003","unstructured":"Katayama H, Brinkley WR, Sen S. The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev. 2003;22(4):451\u2013464.","journal-title":"Cancer Metastasis Rev"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0431"},{"issue":"22","key":"e_1_3_3_16_1","doi-asserted-by":"crossref","first-page":"9118","DOI":"10.1158\/0008-5472.CAN-10-1246","article-title":"The mitotic kinase Aurora-A induces mammary cell migration and breast cancer metastasis by activating the Cofilin-F-actin pathway","volume":"70","author":"Wang L-h","year":"2010","unstructured":"Wang L-h, Xiang J, Yan M, Zhang Y, Zhao Y, Yue C-f, Xu J, Zheng F-m, Chen J-n, Kang Z, et al. The mitotic kinase Aurora-A induces mammary cell migration and breast cancer metastasis by activating the Cofilin-F-actin pathway. Cancer Res. 2010;70(22):9118\u20139128.","journal-title":"Cancer Res"},{"issue":"10","key":"e_1_3_3_17_1","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1158\/1078-0432.CCR-06-2319","article-title":"Aurora-A and p16 polymorphisms contribute to an earlier age at diagnosis of pancreatic cancer in Caucasians","volume":"13","author":"Chen J","year":"2007","unstructured":"Chen J, Li D, Wei C, Sen S, Killary AM, Amos CI, Evans DB, Abbruzzese JL, Frazier ML. Aurora-A and p16 polymorphisms contribute to an earlier age at diagnosis of pancreatic cancer in Caucasians. Clin Cancer Res. 2007;13(10):3100\u20133104.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"e_1_3_3_18_1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3233\/CBM-160238","article-title":"Aurora-A regulates autophagy through the Akt pathway in human prostate cancer","volume":"19","author":"Zhang S","year":"2017","unstructured":"Zhang S, Li J, Zhou G, Mu D, Yan J, Xing J, Yao Z, Sheng H, Li D, Lv C, et al. Aurora-A regulates autophagy through the Akt pathway in human prostate cancer. Cancer Biomark. 2017;19(1):27\u201334.","journal-title":"Cancer Biomark"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2775"},{"issue":"8","key":"e_1_3_3_20_1","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1097\/IGC.0000000000001081","article-title":"Inhibition of aurora kinase A synergistically enhances cytotoxicity in ovarian clear cell carcinoma cell lines induced by cisplatin: a potential treatment strategy","volume":"27","author":"Chiba Y","year":"2017","unstructured":"Chiba Y, Sato S, Itamochi H, Yoshino N, Fukagawa D, Kawamura H, Suga Y, Kojima-Chiba A, Muraki Y, Sugai T, et al. Inhibition of aurora kinase A synergistically enhances cytotoxicity in ovarian clear cell carcinoma cell lines induced by cisplatin: a potential treatment strategy. Int J Gynecol Cancer. 2017;27(8):1666\u20131674.","journal-title":"Int J Gynecol Cancer"},{"issue":"11","key":"e_1_3_3_21_1","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1158\/0008-5472.CAN-09-3953","article-title":"Aurora-a is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells","volume":"70","author":"Cammareri P","year":"2010","unstructured":"Cammareri P, Scopelliti A, Todaro M, Eterno V, Francescangeli F, Moyer MP, Agrusa A, Dieli F, Zeuner A, Stassi G, et al. Aurora-a is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells. Cancer Res. 2010;70(11):4655\u20134665.","journal-title":"Cancer Res"},{"issue":"10","key":"e_1_3_3_22_1","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.1158\/0008-5472.CAN-05-2796","article-title":"Targeting Aurora kinases for the treatment of prostate cancer","volume":"66","author":"Lee ECY","year":"2006","unstructured":"Lee ECY, Frolov A, Li R, Ayala G, Greenberg NM. Targeting Aurora kinases for the treatment of prostate cancer. Cancer Res. 2006;66(10):4996\u20135002.","journal-title":"Cancer Res"},{"issue":"23","key":"e_1_3_3_23_1","first-page":"6803","article-title":"Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft","volume":"62","author":"Bar-Shira A","year":"2002","unstructured":"Bar-Shira A, et al. Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft. Cancer Res. 2002;62(23):6803\u20136807.","journal-title":"Cancer Res"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2008.22"},{"issue":"43","key":"e_1_3_3_25_1","doi-asserted-by":"crossref","first-page":"22854","DOI":"10.1074\/jbc.A110.121129","article-title":"Phosphorylation and activation of androgen receptor by Aurora-A","volume":"291","author":"Shu S-K","year":"2016","unstructured":"Shu S-K, Liu Q, Coppola D, Cheng JQ. Phosphorylation and activation of androgen receptor by Aurora-A. J Biol Chem. 2016;291(43):22854.","journal-title":"J Biol Chem"},{"issue":"1","key":"e_1_3_3_26_1","doi-asserted-by":"crossref","first-page":"40957","DOI":"10.1038\/srep40957","article-title":"Aurora A regulates expression of AR-V7 in models of castrate resistant prostate cancer","volume":"7","author":"Jones D","year":"2017","unstructured":"Jones D, Noble M, Wedge SR, Robson CN, Gaughan L. Aurora A regulates expression of AR-V7 in models of castrate resistant prostate cancer. Sci Rep. 2017;7(1):40957.","journal-title":"Sci Rep"},{"issue":"1","key":"e_1_3_3_27_1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1479-5876-6-79","article-title":"Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells","volume":"6","author":"Scharer CD","year":"2008","unstructured":"Scharer CD, Laycock N, Osunkoya AO, Logani S, McDonald JF, Benigno BB, Moreno CS. Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells. J Transl Med. 2008;6(1):79.","journal-title":"J Transl Med"},{"issue":"4","key":"e_1_3_3_28_1","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1158\/1535-7163.MCT-08-0754","article-title":"The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model","volume":"8","author":"VanderPorten EC","year":"2009","unstructured":"VanderPorten EC, Taverna P, Hogan JN, Ballinger MD, Flanagan WM, Fucini RV. The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model. Mol Cancer Ther. 2009;8(4):930\u2013939.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"e_1_3_3_29_1","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00018-012-1073-7","article-title":"Aurora A kinase (AURKA) in normal and pathological cell division","volume":"70","author":"Nikonova AS","year":"2013","unstructured":"Nikonova AS, Astsaturov I, Serebriiskii IG, Dunbrack RL, Golemis EA. Aurora A kinase (AURKA) in normal and pathological cell division. Cell Mol Life Sci. 2013;70(4):661\u2013687.","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"e_1_3_3_30_1","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2352-3026(19)30203-0","article-title":"Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial","volume":"7","author":"Brunner AM","year":"2020","unstructured":"Brunner AM, Blonquist TM, DeAngelo DJ, McMasters M, Fell G, Hermance NM, Winer ES, Lindsley RC, Hobbs GS, Amrein PC, et al. Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020;7(2):e122\u2013e133.","journal-title":"Lancet Haematol"},{"issue":"9","key":"e_1_3_3_31_1","doi-asserted-by":"crossref","first-page":"6442","DOI":"10.1111\/jcmm.14538","article-title":"Aurora kinase A stabilizes FOXM1 to enhance paclitaxel resistance in triple\u2010negative breast cancer","volume":"23","author":"Yang N","year":"2019","unstructured":"Yang N, Wang C, Wang J, Wang Z, Huang D, Yan M, Kamran M, Liu Q, Xu B. Aurora kinase A stabilizes FOXM1 to enhance paclitaxel resistance in triple\u2010negative breast cancer. J Cell Mol Med. 2019;23(9):6442\u20136453.","journal-title":"J Cell Mol Med"},{"issue":"5","key":"e_1_3_3_32_1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s11523-019-00662-4","article-title":"Inhibition of Aurora A kinase in combination with chemotherapy induces synthetic lethality and overcomes chemoresistance in Myc-overexpressing lymphoma: SI Park et al","volume":"14","author":"Park SI","year":"2019","unstructured":"Park SI, Lin CP, Ren N, Angus SP, Dittmer DP, Foote M, Parton T, Bhatt AP, Fedoriw YD, Roth DP, et al. Inhibition of Aurora A kinase in combination with chemotherapy induces synthetic lethality and overcomes chemoresistance in Myc-overexpressing lymphoma: SI Park et al. Target Oncol. 2019;14(5):563\u2013575.","journal-title":"Target Oncol"},{"issue":"50","key":"e_1_3_3_33_1","doi-asserted-by":"crossref","first-page":"52175","DOI":"10.1074\/jbc.M406802200","article-title":"Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215","volume":"279","author":"Liu Q","year":"2004","unstructured":"Liu Q, Kaneko S, Yang L, Feldman RI, Nicosia SV, Chen J, Cheng JQ. Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem. 2004;279(50):52175\u201352182.","journal-title":"J Biol Chem"},{"issue":"2","key":"e_1_3_3_34_1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1097-2765(01)00323-9","article-title":"Regulation of PTEN transcription by p53","volume":"8","author":"Stambolic V","year":"2001","unstructured":"Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y, Benchimol S, Mak TW. Regulation of PTEN transcription by p53. Mol Cell. 2001;8(2):317\u2013325.","journal-title":"Mol Cell"},{"issue":"8","key":"e_1_3_3_35_1","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1101\/gad.973602","article-title":"p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas","volume":"16","author":"Singh B","year":"2002","unstructured":"Singh B, Reddy PG, Goberdhan A, Walsh C, Dao S, Ngai I, Chou TC, O-Charoenrat P, Levine AJ, Rao PH, et al. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes Dev. 2002;16(8):984\u2013993.","journal-title":"Genes Dev"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.22113"},{"issue":"18","key":"e_1_3_3_37_1","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1158\/0008-5472.CAN-16-2055","article-title":"p21 (WAF1) mediates cell-cycle inhibition, relevant to cancer suppression and therapy","volume":"76","author":"El-Deiry WS.","year":"2016","unstructured":"El-Deiry WS. p21 (WAF1) mediates cell-cycle inhibition, relevant to cancer suppression and therapy. Cancer Res. 2016;76(18):5189\u20135191.","journal-title":"Cancer Res"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05541"},{"issue":"2","key":"e_1_3_3_39_1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2174\/156800908783769337","article-title":"p53: a guide to apoptosis","volume":"8","author":"Meulmeester E","year":"2008","unstructured":"Meulmeester E, Jochemsen AG. p53: a guide to apoptosis. Curr Cancer Drug Targets. 2008;8(2):87\u201397.","journal-title":"Curr Cancer Drug Targets"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/35106009"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22154"},{"issue":"1","key":"e_1_3_3_42_1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/ng1279","article-title":"Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53","volume":"36","author":"Katayama H","year":"2004","unstructured":"Katayama H, Sasai K, Kawai H, Yuan Z-M, Bondaruk J, Suzuki F, Fujii S, Arlinghaus RB, Czerniak BA, Sen S, et al. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet. 2004;36(1):55\u201362.","journal-title":"Nat Genet"},{"issue":"18","key":"e_1_3_3_43_1","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.4161\/cc.21732","article-title":"p53 negatively regulates Aurora A via both transcriptional and posttranslational regulation","volume":"11","author":"Wu C-C","year":"2012","unstructured":"Wu C-C, Yang T-Y, Yu C-TR, Phan L, Ivan C, Sood AK, Hsu S-L, Lee M-H. p53 negatively regulates Aurora A via both transcriptional and posttranslational regulation. Cell Cycle. 2012;11(18):3433\u20133442.","journal-title":"Cell Cycle"},{"issue":"5","key":"e_1_3_3_44_1","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1158\/1541-7786.MCR-08-0483","article-title":"Aurora-A overexpression in mouse liver causes p53-dependent premitotic arrest during liver regeneration","volume":"7","author":"Li C-C","year":"2009","unstructured":"Li C-C, Chu H-Y, Yang C-W, Chou C-K, Tsai T-F. Aurora-A overexpression in mouse liver causes p53-dependent premitotic arrest during liver regeneration. Mol Cancer Res. 2009;7(5):678\u2013688.","journal-title":"Mol Cancer Res"},{"issue":"54","key":"e_1_3_3_45_1","doi-asserted-by":"crossref","first-page":"8720","DOI":"10.1038\/sj.onc.1208153","article-title":"Cre-loxP-controlled periodic Aurora-A overexpression induces mitotic abnormalities and hyperplasia in mammary glands of mouse models","volume":"23","author":"Zhang D","year":"2004","unstructured":"Zhang D, Hirota T, Marumoto T, Shimizu M, Kunitoku N, Sasayama T, Arima Y, Feng L, Suzuki M, Takeya M, et al. Cre-loxP-controlled periodic Aurora-A overexpression induces mitotic abnormalities and hyperplasia in mammary glands of mouse models. Oncogene. 2004;23(54):8720\u20138730.","journal-title":"Oncogene"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-3171"},{"issue":"10","key":"e_1_3_3_47_1","first-page":"2717","article-title":"Inhibition of proliferation, viability, migration and invasion of gastric cancer cells by Aurora-A deletion","volume":"12","author":"Wang W","year":"2011","unstructured":"Wang W, Zhang N, Wang J, Bu X-M, Zhao C-H. Inhibition of proliferation, viability, migration and invasion of gastric cancer cells by Aurora-A deletion. Asian Pac J Cancer Prev. 2011;12(10):2717\u20132720.","journal-title":"Asian Pac J Cancer Prev"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-09-0300"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-013-1393-8"},{"issue":"1","key":"e_1_3_3_50_1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12943-025-02353-3","article-title":"Aurora kinases signaling in cancer: from molecular perception to t therapies","volume":"24","author":"Vats P","year":"2025","unstructured":"Vats P, Saini C, Baweja B, Srivastava SK, Kumar A, Kushwah AS, Nema R. Aurora kinases signaling in cancer: from molecular perception to t therapies. Mol Cancer. 2025;24(1):180.","journal-title":"Mol Cancer"},{"key":"e_1_3_3_51_1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/B978-0-323-91287-7.00028-4","volume-title":"Protein kinase inhibitors","author":"Varshney N","year":"2022","unstructured":"Varshney N, et al. Chapter 10-Aurora kinase: an emerging potential target in therapeutics. In: Protein kinase inhibitors. Cambridge, MA: Academic Press; 2022. p. 261\u2013322."},{"issue":"8","key":"e_1_3_3_52_1","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1200\/JCO.18.00899","article-title":"Randomized phase III study of alisertib or investigator\u2019s choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma","volume":"37","author":"O\u2019Connor OA","year":"2019","unstructured":"O\u2019Connor OA, \u00d6zcan M, Jacobsen ED, Roncero JM, Trotman J, Demeter J, Masszi T, Pereira J, Ramchandren R, Beaven A, et al. Randomized phase III study of alisertib or investigator\u2019s choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma. JCO. 2019;37(8):613\u2013623.","journal-title":"JCO"},{"issue":"5","key":"e_1_3_3_53_1","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2011.08898.x","article-title":"The potential role of Aurora kinase inhibitors in haematological malignancies","volume":"155","author":"Farag SS.","year":"2011","unstructured":"Farag SS. The potential role of Aurora kinase inhibitors in haematological malignancies. Br J Haematol. 2011;155(5):561\u2013579.","journal-title":"Br J Haematol"},{"issue":"1","key":"e_1_3_3_54_1","doi-asserted-by":"crossref","first-page":"28528","DOI":"10.1038\/srep28528","article-title":"Allosteric modulation of AURKA kinase activity by a small-molecule inhibitor of its protein-protein interaction with TPX2","volume":"6","author":"Jane\u010dek M","year":"2016","unstructured":"Jane\u010dek M, Rossmann M, Sharma P, Emery A, Huggins DJ, Stockwell SR, Stokes JE, Tan YS, Almeida EG, Hardwick B, et al. Allosteric modulation of AURKA kinase activity by a small-molecule inhibitor of its protein-protein interaction with TPX2. Sci Rep. 2016;6(1):28528.","journal-title":"Sci Rep"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c01165"},{"key":"e_1_3_3_56_1","doi-asserted-by":"crossref","first-page":"e02667","DOI":"10.7554\/eLife.02667","article-title":"Molecular mechanism of Aurora A kinase autophosphorylation and its allosteric activation by TPX2","volume":"3","author":"Zorba A","year":"2014","unstructured":"Zorba A, Buosi V, Kutter S, Kern N, Pontiggia F, Cho Y-J, Kern D. Molecular mechanism of Aurora A kinase autophosphorylation and its allosteric activation by TPX2. Elife. 2014;3:e02667.","journal-title":"Elife"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.6b00727"},{"issue":"1","key":"e_1_3_3_58_1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41392-024-02107-5","article-title":"Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines","volume":"10","author":"Xiao W","year":"2025","unstructured":"Xiao W, Jiang W, Chen Z, Huang Y, Mao J, Zheng W, Hu Y, Shi J. Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines. Signal Transduct Target Ther. 2025;10(1):74.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"e_1_3_3_59_1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","article-title":"Therapeutic peptides: current applications and future directions","volume":"7","author":"Wang L","year":"2022","unstructured":"Wang L, Wang N, Zhang W, Cheng X, Yan Z, Shao G, Wang X, Wang R, Fu C. Therapeutic peptides: current applications and future directions. Signal Transduct Target Ther. 2022;7(1):48.","journal-title":"Signal Transduct Target Ther"},{"key":"e_1_3_3_60_1","doi-asserted-by":"crossref","first-page":"1302169","DOI":"10.3389\/fchem.2023.1302169","article-title":"Big peptide drugs in a small molecule world","volume":"11","author":"Otvos L","year":"2023","unstructured":"Otvos L, Jr, Wade JD. Big peptide drugs in a small molecule world. Front Chem. 2023;11:1302169.","journal-title":"Front Chem"},{"issue":"19","key":"e_1_3_3_61_1","doi-asserted-by":"crossref","first-page":"32117","DOI":"10.18632\/oncotarget.16738","article-title":"Identification of small molecule inhibitors of the Aurora-A\/TPX2 complex","volume":"8","author":"Asteriti IA","year":"2017","unstructured":"Asteriti IA, Daidone F, Colotti G, Rinaldo S, Lavia P, Guarguaglini G, Paiardini A. Identification of small molecule inhibitors of the Aurora-A\/TPX2 complex. Oncotarget. 2017;8(19):32117\u201332133.","journal-title":"Oncotarget"},{"issue":"23","key":"e_1_3_3_62_1","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.2174\/09298673113209990001","article-title":"Virtual screening strategies in drug discovery: a critical review","volume":"20","author":"Lavecchia A","year":"2013","unstructured":"Lavecchia A, Di Giovanni C. Virtual screening strategies in drug discovery: a critical review. Curr Med Chem. 2013;20(23):2839\u20132860.","journal-title":"Curr Med Chem"},{"issue":"4","key":"e_1_3_3_63_1","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1021\/acsmedchemlett.4c00093","article-title":"The science and art of structure-based virtual screening","volume":"15","author":"Zhao H.","year":"2024","unstructured":"Zhao H. The science and art of structure-based virtual screening. ACS Med Chem Lett. 2024;15(4):436\u2013440.","journal-title":"ACS Med Chem Lett"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031798"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.1c12075"},{"issue":"5","key":"e_1_3_3_66_1","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1021\/acs.jmedchem.5c02435","article-title":"Discovery of a novel dual-targeting KRASG12D\/HDAC peptide inhibitor for the treatment of pancreatic cancer","volume":"69","author":"Zhang Q","year":"2026","unstructured":"Zhang Q, Geng Y, Chen H, Ni J, Guan L, Zhai DQ, Wang Y, Xu S, Niu M-M, Zheng L, et al. Discovery of a novel dual-targeting KRASG12D\/HDAC peptide inhibitor for the treatment of pancreatic cancer. J Med Chem. 2026;69(5):5425\u20135440.","journal-title":"J Med Chem"},{"issue":"9","key":"e_1_3_3_67_1","doi-asserted-by":"crossref","first-page":"7130","DOI":"10.1021\/acs.jmedchem.3c02433","article-title":"Discovery of a potent dual son of sevenless 1 (SOS1) and epidermal growth factor receptor (EGFR) Inhibitor for the treatment of prostate cancer","volume":"67","author":"Zheng L","year":"2024","unstructured":"Zheng L, Zhang Y, Mei S, Xie T, Zou Y, Wang Y, Jing H, Xu S, Dramou P, Xu Z, et al. Discovery of a potent dual son of sevenless 1 (SOS1) and epidermal growth factor receptor (EGFR) Inhibitor for the treatment of prostate cancer. J Med Chem. 2024;67(9):7130\u20137145.","journal-title":"J Med Chem"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117248"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c01572"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.201904969"},{"issue":"1","key":"e_1_3_3_71_1","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3892\/ol.2015.3946","article-title":"Upregulation of ULK1 expression in PC\u20113 cells following tumor protein P53 transfection by sonoporation","volume":"11","author":"Wang YU","year":"2016","unstructured":"Wang YU, Chen Y-N, Zhang W, Yang YU, Bai W-K, Shen E, Hu B. Upregulation of ULK1 expression in PC\u20113 cells following tumor protein P53 transfection by sonoporation. Oncol Lett. 2016;11(1):699\u2013704.","journal-title":"Oncol Lett"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-03127-w"},{"issue":"51","key":"e_1_3_3_73_1","doi-asserted-by":"crossref","first-page":"84718","DOI":"10.18632\/oncotarget.12448","article-title":"The Aurora kinase A inhibitor TC-A2317 disrupts mitotic progression and inhibits cancer cell proliferation","volume":"7","author":"Min YH","year":"2016","unstructured":"Min YH, Kim W, Kim J-E. The Aurora kinase A inhibitor TC-A2317 disrupts mitotic progression and inhibits cancer cell proliferation. Oncotarget. 2016;7(51):84718\u201384735.","journal-title":"Oncotarget"},{"issue":"6","key":"e_1_3_3_74_1","doi-asserted-by":"crossref","first-page":"e21291","DOI":"10.1371\/journal.pone.0021291","article-title":"Control of centrin stability by Aurora A","volume":"6","author":"Lukasiewicz KB","year":"2011","unstructured":"Lukasiewicz KB, Greenwood TM, Negron VC, Bruzek AK, Salisbury JL, Lingle WL. Control of centrin stability by Aurora A. PLoS One. 2011;6(6):e21291.","journal-title":"PLoS One"}],"container-title":["Journal of Enzyme Inhibition and Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14756366.2026.2700842","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14756366.2026.2700842","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14756366.2026.2700842","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T11:14:02Z","timestamp":1786446842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14756366.2026.2700842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/14756366.2026.2700842"],"URL":"https:\/\/doi.org\/10.1080\/14756366.2026.2700842","relation":{},"ISSN":["1475-6366","1475-6374"],"issn-type":[{"value":"1475-6366","type":"print"},{"value":"1475-6374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ienz20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ienz20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-05-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2700842"}}